EndoSpan

Company Overview

Snapshot

Founded in August 2008 by Alon Shalev and Rafi Benary, EndoSpan operates with 51–200 employees. The company has secured funding across 5 rounds from 5 investors. In May 2026, EndoSpan was acquired by Artivion.

Business overview

EndoSpan develops low-profile stent graft systems designed for the treatment of aneurysms and dissections throughout the aorta, including infrarenal, visceral, and thoracic regions. The company's core technology aims to simplify and de-invasify the treatment of aortic lesions, offering solutions for patients with limited traditional treatment options. Its product portfolio includes the HORIZON system, which facilitates single-sided endovascular aneurysm repair (EVAR) procedures, and NEXUS, a modular aortic stent graft system for minimally invasive endovascular repair of aneurysms in the ascending aorta or aortic arch. EndoSpan serves the healthcare and life sciences sectors, specifically targeting medical providers in the cardiovascular and surgical fields.

Strategic signal

In May 2026, EndoSpan was acquired by Artivion, following the FDA approval of its aortic repair system. This acquisition signals a significant validation of EndoSpan's technology and market potential, providing Artivion with advanced solutions in the cardiovascular medical device space and indicating a successful exit for EndoSpan's investors.

Company Intelligence Q&A

What was a significant recent corporate development for EndoSpan?

In May 2026, EndoSpan was acquired by Artivion. This acquisition was triggered by the FDA approval of EndoSpan’s aortic repair system.

When did EndoSpan receive FDA Breakthrough Device designation for its NEXUS system?

In April 2020, the NEXUS aortic arch stent graft system received FDA Breakthrough Device designation.

Which company signed an option to acquire EndoSpan?

In September 2019, CryoLife signed an option to acquire EndoSpan for up to $450 million.

What was a key regulatory milestone for EndoSpan's HORIZON system?

In March 2018, EndoSpan received the CE Mark for its HORIZON EVAR System, based on clinical and pivotal data for treating abdominal aortic aneurysms.

When did EndoSpan secure CE Mark approval for its Nexus stent graft system?

In March 2019, EndoSpan secured CE Mark approval for its Nexus stent graft system to be used for branched endovascular repair in the aortic arch.